Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Science Board noms

This article was originally published in The Tan Sheet

Executive Summary

FDA requests nominations for membership on its Science Board, which advises the commissioner on technical issues, regulatory science and research agendas, according to a Sept. 5 Federal Register notice. Send nominations of individuals knowledgeable in the fields of food safety, nutrition, pharmacology, nanotechnology and other scientific disciplines to FDA at [email protected] by Oct. 6. In May, FDA Commissioner Andrew von Eschenbach said he intends to expand the board from 11 to 21 members and double its annual meetings from two to four in response to a board report pointing to the agency's deficiencies in expertise and technology (2"The Tan Sheet" June 30, 2008, p. 12)

You may also be interested in...



FDA Expects Greater Scientific Impact With Larger Advisory Board

FDA Commissioner Andrew von Eschenbach is attempting to increase the impact of the agency's Science Board Advisory Committee by doubling the number of members and meetings

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

BMS Has A Strong Pipeline, But Access Challenges Remain

Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102082

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel